文献速递心脑血管急症重症综合管理与镇静镇痛

接受直接口服抗凝药的心房颤动患者围手术期管理

Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant.
PubMed 文献 · JAMA Intern Med · 2019-01-01
一句话结论PAUSE研究显示,房颤患者择期手术前按方案中断DOAC、不桥接肝素、不检测凝血功能,30天主要出血和动脉血栓栓塞率低。

PAUSE队列研究在加拿大、美国、欧洲23个中心纳入3007例长期服用阿哌沙班、达比加群酯或利伐沙班的房颤患者,按DOAC药代动力学、手术出血风险和肌酐清除率制定标准化中断与恢复方案:低出血风险手术前停1天、高出血风险手术前停2天,术后低出血风险1天、高出血风险2-3天恢复用药。30天主要出血率阿哌沙班组1.35%、达比加群组0.90%、利伐沙班组1.85%;动脉血栓栓塞率分别为0.16%、0.60%、0.37%。高出血风险手术中,阿哌沙班组主要出血2.96%、利伐沙班组2.95%。该围手术期管理策略不桥接肝素、不检测凝血功能,与低出血和血栓栓塞率相关。

要点

  • 房颤患者择期手术前低出血风险停DOAC 1天、高出血风险停2天,术后低出血风险1天、高出血风险2-3天恢复,不桥接肝素。
  • 30天主要出血率:阿哌沙班组1.35%、达比加群组0.90%、利伐沙班组1.85%。
  • 30天动脉血栓栓塞率:阿哌沙班组0.16%、达比加群组0.60%、利伐沙班组0.37%。
  • 高出血风险手术中主要出血率:阿哌沙班组2.96%、利伐沙班组2.95%。
  • 该策略不检测凝血功能,与低主要出血和动脉血栓栓塞率相关。

适用人群与场景

  • 年龄18岁及以上、长期服用阿哌沙班、达比加群酯或利伐沙班的房颤患者,计划行择期手术或操作,且能遵守DOAC中断方案。

处置流程与药物剂量

  • 低出血风险手术前停用DOAC 1天,高出血风险手术前停用DOAC 2天。
  • 低出血风险手术后1天恢复DOAC,高出血风险手术后2至3天恢复DOAC。
  • 围手术期不桥接肝素,不检测凝血功能。

研究设计与关键结果

  • PAUSE为队列研究,纳入23个中心3007例房颤患者,平均年龄72.5岁(SD 9.39),男性1988例(66.1%);阿哌沙班组1257例(41.8%)、达比加群组668例(22.2%)、利伐沙班组1082例(36.0%);高出血风险手术1007例(33.5%)。
  • 30天术后主要出血率:阿哌沙班组1.35%(95%CI 0%-2.00%)、达比加群组0.90%(95%CI 0%-1.73%)、利伐沙班组1.85%(95%CI 0%-2.65%)。
  • 30天动脉血栓栓塞率:阿哌沙班组0.16%(95%CI 0%-0.48%)、达比加群组0.60%(95%CI 0%-1.33%)、利伐沙班组0.37%(95%CI 0%-0.82%)。
  • 高出血风险手术患者主要出血率:阿哌沙班组2.96%(95%CI 0%-4.68%)、利伐沙班组2.95%(95%CI 0%-4.76%)。

证据类型、等级与局限

  • 证据类型:队列研究(PAUSE研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于长期服用阿哌沙班、达比加群酯或利伐沙班的房颤患者,择期手术前可按出血风险停药1至2天、术后1至3天恢复,不桥接肝素、不检测凝血功能,该策略与低主要出血和动脉血栓栓塞率相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patients with atrial fibrillation (AF) who use a direct oral anticoagulant (DOAC) and request elective surgery or procedure present a common clinical situation yet perioperative management is uncertain.

OBJECTIVE: To investigate the safety of a standardized perioperative DOAC management strategy.

DESIGN, SETTING, AND PARTICIPANTS: The Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) cohort study conducted at 23 clinical centers in Canada, the United States, and Europe enrolled and screened patients from August 1, 2014, through July 31, 2018. Participants (n = 3007) had AF; were 18 years of age or older; were long-term users of apixaban, dabigatran etexilate, or rivaroxaban; were scheduled for an elective surgery or procedure; and could adhere to the DOAC therapy interruption protocol.

INTERVENTIONS: A simple standardized perioperative DOAC therapy interruption and resumption strategy based on DOAC pharmacokinetic properties, procedure-associated bleeding risk, and creatinine clearance levels. The DOAC regimens were omitted for 1 day before a low-bleeding-risk procedure and 2 days before a high-bleeding-risk procedure. The DOAC regimens were resumed 1 day after a low-bleeding-risk procedure and 2 to 3 days after a high-bleeding-risk procedure. Follow-up of patients occurred for 30 days after the operation.

MAIN OUTCOMES AND MEASURES: Major bleeding and arterial thromboembolism (ischemic stroke, systemic embolism, and transient ischemic attack) and the proportion of patients with an undetectable or minimal residual anticoagulant level (<50 ng/mL) at the time of the procedure.

RESULTS: The 3007 patients with AF (mean [SD] age of 72.5 [9.39] years; 1988 men [66.1%]) comprised 1257 (41.8%) in the apixaban cohort, 668 (22.2%) in the dabigatran cohort, and 1082 (36.0%) in the rivaroxaban cohort; 1007 patients (33.5%) had a high-bleeding-risk procedure. The 30-day postoperative rate of major bleeding was 1.35% (95% CI, 0%-2.00%) in the apixaban cohort, 0.90% (95% CI, 0%-1.73%) in the dabigatran cohort, and 1.85% (95% CI, 0%-2.65%) in the rivaroxaban cohort. The rate of arterial thromboembolism was 0.16% (95% CI, 0%-0.48%) in the apixaban cohort, 0.60% (95% CI, 0%-1.33%) in the dabigatran cohort, and 0.37% (95% CI, 0%-0.82%) in the rivaroxaban cohort. In patients with a high-bleeding-risk procedure, the rates of major bleeding were 2.96% (95% CI, 0%-4.68%) in the apixaban cohort and 2.95% (95% CI, 0%-4.76%) in the rivaroxaban cohort.

CONCLUSIONS AND RELEVANCE: In this study, patients with AF who had DOAC therapy interruption for elective surgery or procedure, a perioperative management strategy without heparin bridging or coagulation function testing was associated with low rates of major bleeding and arterial thromboembolism.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019. PMID: 31380891. doi:10.1001/jamainternmed.2019.2431

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。